Malgorzata Nowicka

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

SPEX: A modular end-to-end platform for high-plex tissue spatial omics analysis.

SPEX: A modular end-to-end platform for high-plex tissue spatial omics analysis.

Journal: GigaScience
Published: January 17, 2025

Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.

Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.

Journal: European urology
Published: July 22, 2024

Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer.

Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 23, 2024

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.

Journal: Cancer
Published: November 09, 2023

UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.

UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.

Journal: Cancer chemotherapy and pharmacology
Published: October 27, 2023

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 22, 2022

Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.

Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 11, 2021

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 15, 2021

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment.

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment.

Journal: Blood advances
Published: March 17, 2021

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.

Journal: Blood advances
Published: December 07, 2020

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.

Journal: Nature
Published: August 16, 2020

diffcyt: Differential discovery in high-dimensional cytometry via high-resolution clustering.

diffcyt: Differential discovery in high-dimensional cytometry via high-resolution clustering.

Journal: Communications biology
Published: December 20, 2018
Showing 1-12 of 21

Last Updated: 09/26/2026